Diplomat Pharmacy Inc (NYSE:DPLO) – Investment analysts at William Blair dropped their Q1 2019 EPS estimates for shares of Diplomat Pharmacy in a report released on Saturday. William Blair analyst J. Kreger now forecasts that the company will post earnings per share of $0.38 for the quarter, down from their previous estimate of $0.40. William Blair also issued estimates for Diplomat Pharmacy’s Q2 2019 earnings at $0.35 EPS, Q3 2019 earnings at $0.39 EPS and Q4 2019 earnings at $0.40 EPS.
A number of other equities analysts have also recently issued reports on DPLO. BidaskClub upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Robert W. Baird reiterated a “buy” rating and issued a $20.00 target price on shares of Diplomat Pharmacy in a report on Sunday, September 17th. Needham & Company LLC reiterated a “buy” rating and issued a $23.75 target price (up from $19.75) on shares of Diplomat Pharmacy in a report on Wednesday, October 4th. Zacks Investment Research upgraded Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a report on Tuesday, October 10th. Finally, Mizuho set a $16.00 target price on Diplomat Pharmacy and gave the stock a “hold” rating in a report on Tuesday, October 24th. Five equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $20.94.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company had revenue of $1.12 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business earned $0.21 EPS. Diplomat Pharmacy’s quarterly revenue was down 4.8% compared to the same quarter last year.
Large investors have recently modified their holdings of the business. PNC Financial Services Group Inc. lifted its stake in Diplomat Pharmacy by 46.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock valued at $130,000 after acquiring an additional 2,794 shares in the last quarter. First Allied Advisory Services Inc. bought a new position in Diplomat Pharmacy during the 2nd quarter valued at $183,000. SG Americas Securities LLC bought a new position in Diplomat Pharmacy during the 3rd quarter valued at $191,000. BNP Paribas Arbitrage SA lifted its stake in Diplomat Pharmacy by 57.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,992 shares of the company’s stock valued at $207,000 after acquiring an additional 5,116 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Diplomat Pharmacy by 478.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 14,600 shares of the company’s stock valued at $216,000 after acquiring an additional 12,076 shares in the last quarter. Institutional investors and hedge funds own 72.21% of the company’s stock.
In related news, CFO Atul Kavthekar acquired 2,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares in the company, valued at $30,000. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey G. Park acquired 3,000 shares of the company’s stock in a transaction on Monday, November 20th. The shares were bought at an average price of $15.46 per share, for a total transaction of $46,380.00. Following the completion of the purchase, the director now owns 7,640 shares in the company, valued at approximately $118,114.40. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 15,000 shares of company stock worth $228,780. Company insiders own 30.20% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.